文献速递其他结缔组织病

抗转录中介因子1-γ IgG2同种型与成人皮肌炎合并癌症相关:一项ENMC多国研究

Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

这项ENMC多国回顾性研究纳入132例抗TIF1γ抗体阳性成人皮肌炎患者,其中72例(54.5%)合并癌症。癌症与抗TIF1γ IgG2抗体存在显著关联(P=0.026,OR=2.26,95%CI:1.10,4.76),合并癌症者的IgG2 ALBIA值与IgG ELISA值均更高。作者认为抗TIF1γ IgG2 ALBIA值与IgG ELISA值可作为抗TIF1γ抗体阳性成人皮肌炎合并癌症的生物标志物。

要点

  • 抗TIF1γ IgG2抗体与成人皮肌炎合并癌症显著相关(P=0.026,OR=2.26)。
  • 合并癌症者抗TIF1γ IgG2 ALBIA中位值1.15 AU/ml,高于无癌症者0.50 AU/ml(P=0.042)。
  • 合并癌症者抗TIF1γ IgG ELISA中位值127.5 AU/ml,高于无癌症者93.0 AU/ml(P=0.004)。

核心结论

  • 结果提示可考虑将抗TIF1γ IgG2 ALBIA值与IgG ELISA值作为抗TIF1γ抗体阳性成人皮肌炎合并癌症的生物标志物。

研究设计与样本

  • ENMC多国国际多中心回顾性研究,纳入132例抗TIF1γ抗体阳性的成人皮肌炎患者,平均年龄55±15岁。
  • 纳入标准为符合ENMC标准诊断的皮肌炎、用院内可寻址激光珠免疫分析(ALBIA)从诊断时冻存血清检出抗TIF1γ IgG抗体,并具备基线特征及随访至发生癌症或诊断无癌症者至少随访1年的数据。
  • 抗TIF1γ IgG2抗体检测与定量采用院内ALBIA,抗TIF1γ IgG抗体定量另采用近期ELISA商业试剂盒。

主要发现

  • 132例中72例(54.5%)合并癌症,癌症与抗TIF1γ IgG2抗体的关联有统计学意义(P=0.026),OR=2.26(95%CI:1.10,4.76)。
  • 合并癌症者抗TIF1γ IgG2 ALBIA中位值1.15 AU/ml(IQR:0.14-9.76),无癌症者为0.50 AU/ml(IQR:0.14-1.46),P=0.042。
  • 合并癌症者抗TIF1γ IgG ELISA中位值127.5 AU/ml(IQR:81.5-139.6),无癌症者为93.0 AU/ml(IQR:54.0-132.9),P=0.004。

关键数值与推荐

  • 研究采用ENMC标准诊断皮肌炎,抗TIF1γ IgG2抗体用院内ALBIA检测,抗TIF1γ IgG抗体另用ELISA商业试剂盒定量。
  • 癌症与抗TIF1γ IgG2抗体关联的OR=2.26(95%CI:1.10,4.76),P=0.026。
  • 合并癌症者抗TIF1γ IgG2 ALBIA中位值1.15 AU/ml与无癌症者0.50 AU/ml相比,P=0.042。
  • 合并癌症者抗TIF1γ IgG ELISA中位值127.5 AU/ml与无癌症者93.0 AU/ml相比,P=0.004。

临床怎么用

  • 作者认为,对抗TIF1γ抗体阳性成人皮肌炎,可考虑将抗TIF1γ IgG2 ALBIA值与IgG ELISA值作为合并癌症的生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the role of the anti-TIF1γ auto-antibody (aAb) IgG2 isotype as a biomarker of cancer in anti-TIF1γ aAb-positive adult DM. METHODS: International multicentre retrospective study with the following inclusion criteria: (i) diagnosis of DM according to ENMC criteria; (ii) presence of anti-TIF1γ IgG aAb determined using an in-house addressable laser bead immunoassay (ALBIA) from cryopreserved serums sampled at time of DM diagnosis and (iii) available baseline characteristics and follow-up data until the occurrence of cancer and/or a minimum follow-up of 1 year for patients without known cancer at diagnosis. Detection and quantification of anti-TIF1γ IgG2 aAb was done using the in-house ALBIA. In addition, a recent ELISA commercial kit was used for anti-TIF1γ IgG aAb quantification. RESULTS: A total of 132 patients (mean age 55±15 years) of whom 72 (54.5%) had an associated cancer were analysed. The association between the presence of cancer and the presence of anti-TIF1γ IgG2 aAb was statistically significant (P = 0.026), with an OR of 2.26 (95% CI: 1.10, 4.76). Patients with cancer displayed significantly higher anti-TIF1γ IgG2 aAb ALBIA values with a median value of 1.15 AU/ml (IQR: 0.14-9.76) compared with 0.50 AU/ml (IQR: 0.14-1.46) for patients without cancer (P = 0.042). In addition, patients with cancer displayed significantly higher anti-TIF1γ IgG aAb ELISA values with a median value of 127.5 AU/ml (IQR: 81.5-139.6) compared with 93.0 AU/ml (IQR: 54.0-132.9) for patients without cancer (P = 0.004). CONCLUSION: These results suggest considering anti-TIF1γ IgG2 ALBIA and IgG ELISA values as biomarkers of cancer in anti-TIF1 γ aAb-positive adult DM.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cordel N, Dechelotte B, Jouen F, et al. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study. Rheumatology (Oxford). 2023. PMID: 36250907. doi:10.1093/rheumatology/keac577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。